Provectus Biopharmaceuticals Provides Update on Research into PV-10 Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better
Provectus recently provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene small molecule) as an immune adjuvant in vaccines for cancer and viruses to improve immune response upon vaccination, in conjunction with the company’s ongoing efforts to expand its intellectual property.
On January 20, 2022, the US Patent and Trademark Office (USPTO) published Provectus’ patent application titled Halogenated Xanthenes as Vaccine Adjuvants (publication no. US 2022/0016242 A1), which contained among other things:
- In vitro data that showed PV-10 was able to significantly increase numbers of interferon (IFN) gamma-producing CD8 cells (compared to controls) for peptides representing various antigenic regions of the Hepatitis B virus (HBV) core protein (HBcAg). These peptides were selected for their capability to raise CD4 and CD8 T cells against HBV.
Dominic Rodrigues, Vice Chair of the company’s Board of Directors, said “Immune adjuvants can help vaccines generate quicker, more efficacious and durable immune responses. This new research further supports the multi-faceted immunogenicity of Provectus’ small molecule medical science platform, which is the foundation of our work to develop transformative, accessibly priced immunotherapy medicines.”
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a family of small molecules called halogenated xanthenes. Multi-route of administration drug discovery and development programs include investigational drugs and drug targets in oncology (clinical-stage), dermatology (clinical-stage), hematology, virology, microbiology, ophthalmology (clinical-stage), and animal health. Information about the company’s clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For more information, visit www.provectusbio.com.
Total Page Views: 857
